Gastroenterology & GI Surgery

Welcome to the Mayo Clinic Gastroenterology & GI Surgery Page! With one of the largest group of digestive disease specialists in the world, Mayo Clinic has been recognized as the nation's best Gastroenterology & GI Surgery hospital by U.S. News & World Report. Follow the page to learn about clinical trials and up-to-date research, and find resources for all your gastroenterology needs. Our goal is to connect you to others, and become informed decision makers; so post a comment, share your story, own your health.

PUBLIC PAGE
Fri, Sep 13 10:35am

Sponge on a String – Detecting a Lethal Cancer

By Kanaaz Pereira, Connect Moderator, @kanaazpereira

Esophageal cancer can be lethal. When diagnosed after the onset of symptoms, only 20% of patients have a survival rate of five years.  However, when the disease is diagnosed early, before the onset of symptoms, it can be successfully treated and results in greater than 80% survival at five years.

Esophageal cancer arises from a precancerous condition known as Barrett's esophagus (BE). Currently, BE can only be diagnosed using an endoscope, but only 10% of patients who are eligible to undergo endoscopy take advantage of the screening opportunity. Their reluctance is likely due to the expensive and invasive nature of the procedure that also requires sedation.

Mayo Clinic gastroenterologist, Dr. Prasad Iyer, and his team have developed a new, minimally invasive method – using a compressed sponge on a string, about the size of a multivitamin capsule covered with a dissolvable shell – to diagnose Barrett's esophagus and associated cancer.

A patient undergoing the test swallows the capsule with a few sips of water. As the capsule dissolves it releases the sponge, which is then pulled out using the attached string. The whole procedure takes less than 10 minutes and can be administered by a nurse – the patient does not require sedation.

The sponge provides a rich sample of the entire esophagus – almost a million cells – which are then tested for biomarkers consistent with cancer or pre-cancer. "This test can make widespread screening for Barrett's esophagus feasible,” says Dr. Iyer.

Based on this analysis, researchers have developed promising genetic markers which can predict the presence/absence of BE with 97%–100% accuracy in Phase 1 and Phase 2 trials. They have also developed markers which detect the presence of dysplasia in these same samples. The study documenting the discovery and validation of novel methylated markers, along with results of a pilot study, have been published in the American Journal of Gastroenterology.       

Meet other people, talking about Barrett’s esophagus and esophageal cancer, on Mayo Clinic Connect – join the conversation, share experiences, ask questions, and discover your support network. Here are some discussions you might like to follow...

Please login or register to post a reply.

Invite Others

Send an email to invite people you know to join the Gastroenterology & GI Surgery page.

Please login or register to send an invite.